Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 216

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 216
---
 the aforementioned consolidations. Authorized Share Capital As of December 3, 2025, we had 59,991,852 common shares issued and outstanding and our authorized share capital consists of an unlimited number of common shares, no par value. In the last three years, we have issued an aggregate of 19,293,181 common shares for aggregate net proceeds of $10.9 million net of share issuance costs in several public offerings and private placements. In addition, during the same period, 4,894,456 warrants were exercised for gross proceeds of $5.3 million. In addition to common shares, in the last three years, we have granted (i) share options to employees, directors, consultants and service providers under our Executive Stock Option and Restricted Share Unit Plans exercisable into an aggregate of 1,296,781 common shares, with exercise prices ranging from $23.40 to $642.03 per share; and (ii) an aggregate of 14,020,385 warrants exercisable into common shares, with exercise prices ranging from $0.10 to $243.75 per share, which were issued in three private placements. Common Shares All of our Common Shares are one and the same class, identical in all respects and have equal rights, powers and privileges. Voting.Except as otherwise provided for by resolution of our Board, the holders of outstanding Common Shares have the exclusive right to vote on all matters requiring shareholder action. On each matter on which holders of Common Shares are entitled to vote, each outstanding share of Common Share is entitled to one vote. Dividends.Holders of our Common Shares have equal rights of participation in the dividends and other distributions of our cash, stock or property when, as and if declared thereon by our Board from time to time out of our assets or funds legally available therefor and shall have equal rights to receive our assets and funds available for distribution to shareholders in the event of any liquidation, dissolution or winding up of our affairs, whether voluntary or involuntary. Liquidation.Holders of our Common Shares have equal rights to receive our assets and funds available for distribution to shareholders in the event of any liquidation, dissolution or winding up of our affairs, whether voluntary or involuntary. Rights and Preferences.Holders of our Common Shares will have no preemptive, conversion or subscription rights, and there will be no redemption or sinking funds provisions applicable to our Common Shares. The rights, preferences and privileges of the holders of our Common Shares will be subject to, and may be adversely affected by